“Looking for the very highest quality products and the consistency of a high-tech pharmaceuticals operation? Vida expects to file its licensing application before the end of April, a schedule that should allow it to have the necessary license in hand by the third quarter of this year. In the meantime, the company is raising $1.5 million at $.25 per share. That represents a market value of only $6 million for a company that now owns a 315,000-square-foot production plant with a replacement value estimated at $30 million. Personally, I think this will turn out to be an extraordinary investment. In less than a year’s time, this $.25 financing round is going to look extremely cheap.”
Related posts:
Bitcoin Is Not Quantum-Safe, And How We Can Fix It When Needed
Immovable law collides with unstoppable Bitcoin casinos
Peter King calls for “increased surveillance” of Muslims after Boston
Krugman: Let's Just Print Funny Money
Europe Puts on Its Rally Cap
It’s time to tell the TSA what you really think of it – and for it to listen
Michelle Obama’s Princeton classmate is executive of CGI Federal
Glenn Greenwald: On whistleblowers and government threats of investigation
The Fed’s Dreaded Dilemma: A Weak Economy Plus Inflation
America's New Female Combatants Are Getting Custom Gear
Government Freezes EBT Funds, Orders States to Withhold Food Stamps
During the shutdown, some scientists can't talk about science
Marijuana: The Next Diabetes Drug?
British UKIP Convulsion Significant Threat to Tories
Fox commentator was paid $50,000 to tout stock